Drug Shortage Report for NALOXONE HCL INJECTION - 1MG/ML USP

Last updated on 2022-12-29 History
Report ID 172174
Drug Identification Number 02148714
Brand name NALOXONE HCL INJECTION - 1MG/ML USP
Common or Proper name NALOXONE HCL
Company Name SANDOZ CANADA INCORPORATED
Market Status MARKETED
Active Ingredient(s) NALOXONE HYDROCHLORIDE
Strength(s) 1MG
Dosage form(s) LIQUID
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 2ML
ATC code V03AB
ATC description ALL OTHER THERAPEUTIC PRODUCTS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-10-19
Estimated end date 2023-01-13
Actual end date 2022-12-28
Shortage status Resolved
Updated date 2022-12-29
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 110 RUE DE LAUZON
BOUCHERVILLE, QUEBEC
CANADA J4B 1E6
Company contact information 1 800-361-3062

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v8 2022-12-29 English Compare
v7 2022-12-28 French Compare
v6 2022-12-28 English Compare
v5 2022-11-28 French Compare
v4 2022-11-28 English Compare
v3 2022-10-20 English Compare
v2 2022-10-19 French Compare
v1 2022-10-19 English Compare

Showing 1 to 8 of 8